Migraine - Prophylactic Treatment

• Main Author: Chowdhury Debashish
• Format: Article
• Language: English
• Published: Wolters Kluwer Medknow Publications 2002-01-01
• Series: Annals of Indian Academy of Neurology
• Online Access: http://www.annalsofian.org/article.asp?issn=0972-2327;year=2002;volume=5;issue=1;spage=93;epage=105;aulast=Chowdhury;type=0

Preventive therapy in migraine constitutes an important aspect of migraine management especially in patients who are not controlled or have significant disability despite taking drugs for acute management. In spite of te recent advances in understanding of the pathophysiology of migraine, the mechanisms of action of many preventive drugs are largely unknown. Further, these provide only about 50% reduction in frequency in about 2/3rds of migraine sufferers. Hence, risk-benefit ratio must be considered while prescribing these agents. Recent efforts to undertake large-scale meta-analysis to assess the efficacy of these agents have been rewarding and consensus guidelines have evolved. Propanolol, metoprolol, amitriptyline, sodium valproate, flunarizine and lisuride have emerged as first line drugs. The role of newer anti-convulsants and botox injections in refractory cases are being investigated. Availability, co-morbidities, medical contraindications, concomitant acute therapy and costs are important determinants for choosing a particular agent. This article reviews the guidelines to be followed in choosing the prophylactic treatment options for migraine.